SONN — Sonnet Biotherapeutics Holdings Share Price
0.000.00%
Last trade - 00:00- $3.55m
- $1.49m
- $0.02m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.35 | ||
| Price to Tang. Book | 5.35 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1975.96% | ||
| Return on Equity | -714.96% | ||
| Operating Margin | -1308.09% | ||
Financial Summary
| Year End 30th Sep | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.48 | 0.35 | 0.15 | 0.02 | 1 | n/a | -77.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Directors
- Pankaj Mohan CHM (57)
- John Cross CFO (51)
- John Cini CSO (69)
- Susan Dexter OTH (66)
- Richard Kenney OTH (63)
- Donald Griffith DRC (73)
- Nailesh Bhatt IND (49)
- Albert Dyrness IND (59)
- Raghu Rao IND (59)
- Last Annual
- September 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- October 21st, 1999
- Public Since
- July 27th, 2005
- No. of Shareholders
- 52
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,165,810
- Address
- 100 Overlook Center, Suite 102, PRINCETON, 08540
- Web
- https://www.sonnetbio.com/
- Phone
- +1 6093752227
- Auditors
- KPMG LLP
Upcoming Events for SONN
Sonnet Biotherapeutics Holdings Inc Annual Shareholders Meeting
Q4 2025 Sonnet Biotherapeutics Holdings Inc Earnings Release
Similar to SONN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Sonnet Biotherapeutics Holdings share price?
As of Today at 23:21 UTC, shares in Sonnet Biotherapeutics Holdings are trading at $1.12. This share price information is delayed by 15 minutes.
How has the Sonnet Biotherapeutics Holdings share price performed this year?
Shares in Sonnet Biotherapeutics Holdings last closed at $1.12 and the price had moved by -85.24% over the past 365 days. In terms of relative price strength the Sonnet Biotherapeutics Holdings share price has underperformed the S&P500 Index by -86.94% over the past year.
What are the analyst and broker recommendations for Sonnet Biotherapeutics Holdings?
The overall consensus recommendation for Sonnet Biotherapeutics Holdings is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sonnet Biotherapeutics Holdings dividend yield?
Sonnet Biotherapeutics Holdings does not currently pay a dividend.
Does Sonnet Biotherapeutics Holdings pay a dividend?
Sonnet Biotherapeutics Holdings does not currently pay a dividend.
When does Sonnet Biotherapeutics Holdings next pay dividends?
Sonnet Biotherapeutics Holdings does not currently pay a dividend.
How do I buy Sonnet Biotherapeutics Holdings shares?
To buy shares in Sonnet Biotherapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sonnet Biotherapeutics Holdings?
As of the previous close price of $1.12, shares in Sonnet Biotherapeutics Holdings had a market capitalisation of $3.55m.
Where are Sonnet Biotherapeutics Holdings shares listed?
Here are the trading details for Sonnet Biotherapeutics Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SONN
What kind of share is Sonnet Biotherapeutics Holdings?
Based on an overall assessment of its quality, value and momentum Sonnet Biotherapeutics Holdings is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sonnet Biotherapeutics Holdings share price forecast for 2025?
The analyst consensus target price for shares in Sonnet Biotherapeutics Holdings is $20.00. That is 1685.71% above the last closing price of $1.12.
Analysts covering Sonnet Biotherapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$3.46 for the next financial year.
Find out moreWhat is the trend in the Sonnet Biotherapeutics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sonnet Biotherapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -29.03%.
As of the last closing price of $1.12, shares in Sonnet Biotherapeutics Holdings were trading -54.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sonnet Biotherapeutics Holdings PE Ratio?
The Sonnet Biotherapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sonnet Biotherapeutics Holdings?
Sonnet Biotherapeutics Holdings' management team is headed by:
- Pankaj Mohan - CHM
- John Cross - CFO
- John Cini - CSO
- Susan Dexter - OTH
- Richard Kenney - OTH
- Donald Griffith - DRC
- Nailesh Bhatt - IND
- Albert Dyrness - IND
- Raghu Rao - IND